Please login to the form below
Omeros phase III knee surgery drug fails
A Omeros Corporation drug developed to increase mobility and reduce pain in patients who have undergone arthroscopic knee surgery has failed to meet the primary endpoints of a phase III programme
Omeros Corporation's lead product candidate, a drug intended to increase mobility and reduce pain in patients who have undergone arthroscopic knee surgery, has failed to meet the primary endpoints of a phase III programme because of confounding factors that made it impossible to draw conclusions from the research, according to the company.
The drug was being evaluated in patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction surgery, an indication for which no other pharmaceuticals are approved in the US. Currently known as OMS103HP, it is a proprietary combination of ketoprofen, amytriptyline and oxymetazoline that is injected into standard arthroscopic irrigation solutions and perfused through the knee during surgery.
"Our analysis of the data does not demonstrate a lack of drug effect nor does it appear to undermine the viability of our phase III-ready OMS103HP programme for meniscectomy surgery," said Omeros Chairman and CEO Gregory A Demopulos. "As we learn more from our data analysis, we will provide additional information on our plans for OMS103HP."
An earlier phase I/II study of OMS103HP conducted at Stanford University in patients undergoing arthroscopic knee surgery for ACL reconstruction showed statistically significant improvement in postoperative knee range of motion and function, better pain management and earlier return to work, according to Omeros.
Share
Related Hub content
Subscribe to our email news alerts
- Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn
- Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn
- Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration
- Novavax’s updated COVID-19 vaccine approved by FDA for emergency use
- Alzheimer’s Research UK awards Cardiff University researchers £387,000
- Actinic keratosis – a common skin condition that can lead to skin cancer
No results were found
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
